Roelf Valkema

Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide: The rotterdam experience

Roelf Valkema, Marion de Jong, Willem H. Bakker et al. · Seminars in Nuclear Medicine · 2002 · 430 citations

Medicine, Radionuclide Therapy, Peptide Library +8

Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.

Dik J. Kwekkeboom, Jan Mueller‐Brand, Giovanni Paganelli et al. · PubMed · 2005 · 375 citations

Tumor Regression, Oncology, Engineering +15

Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate.

Roelf Valkema, Stanislas Pauwels, Larry K. Kvols et al. · PubMed · 2005 · 334 citations

Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study

Bo Jan Noordman, Manon C.W. Spaander, Roelf Valkema et al. · The Lancet Oncology · 2018 · 320 citations

Residual Disease, Surgical Oncology, Esophageal Cancer +11

Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine

Edgar J. Rolleman, Roelf Valkema, Marion de Jong et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2003 · 313 citations

Effective Inhibition, Renal Function, Biochemistry +6